EANS-Adhoc: - Marseille-Kliniken AG appoints two Management Board members - New Management Board function strengthens IT development
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement.
03.03.2010
Berlin, 3 March 2010. Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA) has appointed Claus Dobrowolski (53) and Axel Regenhardt (46) to the Management Board. Claus Dobrowolski is to head Finance from 2 April 2010, while Axel Regenhardt is to assume responsibility for a new function on the Management Board with immediate effect, managing IT, Operations and Auditing at the listed health services provider. Axel Hölzer, in charge of operating business at Marseille-Kliniken AG since 2002, will remain CEO.
Claus Dobrowolski holds a degree in business administration and is currently in an executive position at Sasol Germany as Director - Special Assignments. The company is part of the South African Sasol Group, employs around 1,500 employees in Germany and produces surfactants and their primary products, inorganic speciality chemicals and olefins. Dobrowolski was a member of the Executive Board at Sasol Wax International AG, the global leader in the field of paraffin wax and paraffin related products, for seven years until March 2009 and as CFO (Chief Financial Officer) was also responsible for strategy in addition to finance.
IT specialist Axel Regenhardt has held a number of executive positions within the group of companies in Marseille-Kliniken AG. In his previous position, he was the Group´s general agent and the director of Business Service Management at VDSE GmbH (an administration service provider for social institutions). The company develops and implements custom IT solutions for care, rehabilitation and acute care institutions operated by the health service provider.
By installing the new function on the Management Board, Marseille-Kliniken AG is strengthening its business activities in the IT sector. The last few years have seen the Group make substantial investments into software development. At the moment, the Company owns more than 20 software solutions, which are deployed to structure processes in companies providing services in the field of healthcare. The focus of IT applications is on safeguarding and reviewing quality inside care institutions. The Group is planning to enhance its activities in this segment.
End of ad hoc release
end of announcement euro adhoc
Further inquiry note:
Hillermann Consulting
Christian Hillermann
Investor Relations for Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg
Germany
Tel.: +49-(0)40 / 320 279-10
Fax: +49-(0)40 / 320 279-114
www.hillermann-consulting.de
Marseille-Kliniken AG
Dr. Ute Buchheim
Friedrich-Ebert-Str. 65
33330 Gütersloh
Germany
Tel.: +49-(0)5241/90 39-35
Fax: +49-(0)5241/90 39-39
www.marseille-kliniken.com
Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hamburg / regulated dealing